The First and Only Buffered Solution for the Treatment of Osteoporosis

Binosto® (buffered soluble alendronate 70mg) is indicated for the treatment of osteoporosis.

Pharmaceutical Form1

Binosto® is an effervescent tablet containing the active substance alendronic acid  (commonly called alendronate) that represents an efficacious treatment option for osteoporosis. Binosto® is taken once a week as an oral solution. The effervescent tablet must be dissolved in half a glass of water. Binosto® thus prevents the risk of the tablet getting lodged in the esophagus. Binosto® represents a novel therapeutic option, especially for patients who prefer not to swallow tablets or have difficulties swallowing pills. Binosto® has the potential to improve long-term patient compliance and adherence to the therapy, thereby decreasing the risk of disabling fractures.


Switzerland: Binosto is indicated for the treatment of osteoporosis in postmenopausal women and men.2

Europe / UK: Treatment of osteoporosis in postmenopausal women. Binosto® 70 mg reduces the risk of vertebral and hip fractures.3

United States: Treatment of osteoporosis in postmenopausal women. Binosto® increases bone mass and reduces the incidence of fractures, including those of the hip and spine. Binosto® is indicated for treatment to increase bone mass in men with osteoporosis.
Visit for U.S. approved prescribing information.

Disclaimer: Please refer to the official prescribing information in your country regarding the indications, contraindications and warnings.


Global Footprint

Binosto® is commercialized in the United States and in selected countries in Europe, Middle East and Asia.


Out-Licensing of Binosto® distribution rights in LATAM and other selected territories

EffRx seeks to further expand Binosto’s footprint to countries where the product is not yet marketed, particularly in North Africa and Latin America.


1. Binosto Summary of Product Characteristics. June 2021;


3. Binosto Summary of Product Characteristics. June 2021 and